Valerian/Cascade mixture promotes sleep by increasing non-rapid eye movement (NREM) in rodent model

Hyeon Son Choi, Ki Bae Hong, Sung Hee Han, Hyung Joo Suh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The aim of this study was to investigate the beneficial effect of Valerian/Cascade mixture on sleeping in mammal models. In pentobarbital-induced sleep model, Valerian, Cascade, and Valerian/Cascade mixture significantly reduced the latency time for sleeping, and total sleeping time effectively increased in these sample groups compared with the control. Valerian/Cascade mixture increased sleep duration by 37%. The mixture significantly increased the non-rapid eye movement (NREM) sleep time by 53% compared with the control, while REM sleeping time was decreased by 33% with Valerian/Cascade mixture, in Electroencephalography (EEG) analysis, resulting in the increase of total sleep time and the decrease of awakening. This sleep-promoting effect was obvious in caffeine-induced awakening model; Valerian, Cascade, and the mixture significantly enhanced NREM and total sleep time, which were reduced by caffeine. Caffeine-induced increase of awakening was effectively deceased to the normal level by these three samples. In particular, delta wave responsible for deep sleep in NREM was greatly increased by the mixture in both normal and caffeine-induced awake models. This sleep-promoting effect of Valerian/Cascade mixture was shown to be due to the upregulation of gamma-aminobutyric acid A receptor (GABAAR). Valerian/Cascade mixture showed 91% binding capacity to GABAA-BZD receptor. Two compounds, Valerenic acid and Xanthohumol, were shown to significantly contribute to the binding activity of Valerian/Cascade mixture on the GABA receptor.

Original languageEnglish
Pages (from-to)913-920
Number of pages8
JournalBiomedicine and Pharmacotherapy
Volume99
DOIs
Publication statusPublished - 2018 Mar 1

Fingerprint

Valerian
Eye Movements
Rodentia
Sleep
Caffeine
GABA Receptors
Pentobarbital
GABA-A Receptors
Electroencephalography
Mammals
Up-Regulation

Keywords

  • Cascade
  • GABA receptor
  • Non-rapid eye movement
  • Sleep-promotion
  • Valerian

ASJC Scopus subject areas

  • Pharmacology

Cite this

Valerian/Cascade mixture promotes sleep by increasing non-rapid eye movement (NREM) in rodent model. / Choi, Hyeon Son; Hong, Ki Bae; Han, Sung Hee; Suh, Hyung Joo.

In: Biomedicine and Pharmacotherapy, Vol. 99, 01.03.2018, p. 913-920.

Research output: Contribution to journalArticle

@article{a0bb212adf0c44e793ea5d16a59d84be,
title = "Valerian/Cascade mixture promotes sleep by increasing non-rapid eye movement (NREM) in rodent model",
abstract = "The aim of this study was to investigate the beneficial effect of Valerian/Cascade mixture on sleeping in mammal models. In pentobarbital-induced sleep model, Valerian, Cascade, and Valerian/Cascade mixture significantly reduced the latency time for sleeping, and total sleeping time effectively increased in these sample groups compared with the control. Valerian/Cascade mixture increased sleep duration by 37{\%}. The mixture significantly increased the non-rapid eye movement (NREM) sleep time by 53{\%} compared with the control, while REM sleeping time was decreased by 33{\%} with Valerian/Cascade mixture, in Electroencephalography (EEG) analysis, resulting in the increase of total sleep time and the decrease of awakening. This sleep-promoting effect was obvious in caffeine-induced awakening model; Valerian, Cascade, and the mixture significantly enhanced NREM and total sleep time, which were reduced by caffeine. Caffeine-induced increase of awakening was effectively deceased to the normal level by these three samples. In particular, delta wave responsible for deep sleep in NREM was greatly increased by the mixture in both normal and caffeine-induced awake models. This sleep-promoting effect of Valerian/Cascade mixture was shown to be due to the upregulation of gamma-aminobutyric acid A receptor (GABAAR). Valerian/Cascade mixture showed 91{\%} binding capacity to GABAA-BZD receptor. Two compounds, Valerenic acid and Xanthohumol, were shown to significantly contribute to the binding activity of Valerian/Cascade mixture on the GABA receptor.",
keywords = "Cascade, GABA receptor, Non-rapid eye movement, Sleep-promotion, Valerian",
author = "Choi, {Hyeon Son} and Hong, {Ki Bae} and Han, {Sung Hee} and Suh, {Hyung Joo}",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.biopha.2018.01.159",
language = "English",
volume = "99",
pages = "913--920",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",

}

TY - JOUR

T1 - Valerian/Cascade mixture promotes sleep by increasing non-rapid eye movement (NREM) in rodent model

AU - Choi, Hyeon Son

AU - Hong, Ki Bae

AU - Han, Sung Hee

AU - Suh, Hyung Joo

PY - 2018/3/1

Y1 - 2018/3/1

N2 - The aim of this study was to investigate the beneficial effect of Valerian/Cascade mixture on sleeping in mammal models. In pentobarbital-induced sleep model, Valerian, Cascade, and Valerian/Cascade mixture significantly reduced the latency time for sleeping, and total sleeping time effectively increased in these sample groups compared with the control. Valerian/Cascade mixture increased sleep duration by 37%. The mixture significantly increased the non-rapid eye movement (NREM) sleep time by 53% compared with the control, while REM sleeping time was decreased by 33% with Valerian/Cascade mixture, in Electroencephalography (EEG) analysis, resulting in the increase of total sleep time and the decrease of awakening. This sleep-promoting effect was obvious in caffeine-induced awakening model; Valerian, Cascade, and the mixture significantly enhanced NREM and total sleep time, which were reduced by caffeine. Caffeine-induced increase of awakening was effectively deceased to the normal level by these three samples. In particular, delta wave responsible for deep sleep in NREM was greatly increased by the mixture in both normal and caffeine-induced awake models. This sleep-promoting effect of Valerian/Cascade mixture was shown to be due to the upregulation of gamma-aminobutyric acid A receptor (GABAAR). Valerian/Cascade mixture showed 91% binding capacity to GABAA-BZD receptor. Two compounds, Valerenic acid and Xanthohumol, were shown to significantly contribute to the binding activity of Valerian/Cascade mixture on the GABA receptor.

AB - The aim of this study was to investigate the beneficial effect of Valerian/Cascade mixture on sleeping in mammal models. In pentobarbital-induced sleep model, Valerian, Cascade, and Valerian/Cascade mixture significantly reduced the latency time for sleeping, and total sleeping time effectively increased in these sample groups compared with the control. Valerian/Cascade mixture increased sleep duration by 37%. The mixture significantly increased the non-rapid eye movement (NREM) sleep time by 53% compared with the control, while REM sleeping time was decreased by 33% with Valerian/Cascade mixture, in Electroencephalography (EEG) analysis, resulting in the increase of total sleep time and the decrease of awakening. This sleep-promoting effect was obvious in caffeine-induced awakening model; Valerian, Cascade, and the mixture significantly enhanced NREM and total sleep time, which were reduced by caffeine. Caffeine-induced increase of awakening was effectively deceased to the normal level by these three samples. In particular, delta wave responsible for deep sleep in NREM was greatly increased by the mixture in both normal and caffeine-induced awake models. This sleep-promoting effect of Valerian/Cascade mixture was shown to be due to the upregulation of gamma-aminobutyric acid A receptor (GABAAR). Valerian/Cascade mixture showed 91% binding capacity to GABAA-BZD receptor. Two compounds, Valerenic acid and Xanthohumol, were shown to significantly contribute to the binding activity of Valerian/Cascade mixture on the GABA receptor.

KW - Cascade

KW - GABA receptor

KW - Non-rapid eye movement

KW - Sleep-promotion

KW - Valerian

UR - http://www.scopus.com/inward/record.url?scp=85041647331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041647331&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2018.01.159

DO - 10.1016/j.biopha.2018.01.159

M3 - Article

C2 - 29710491

AN - SCOPUS:85041647331

VL - 99

SP - 913

EP - 920

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

ER -